LIFECORE BIOMEDICAL, INC. Paid-in-Kind Interest
LIFECORE BIOMEDICAL, INC. (LFCR) reported Paid-in-Kind Interest of $13.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. paid-in-kind interest for the quarter ending 2026-06-30 was $6.86M.
- LIFECORE BIOMEDICAL, INC. paid-in-kind interest for the quarter ending 2026-03-31 was $7.08M.
- LIFECORE BIOMEDICAL, INC. paid-in-kind interest for the quarter ending 2025-09-30 was $6.11M.
- LIFECORE BIOMEDICAL, INC. paid-in-kind interest for the quarter ending 2025-05-25 was $5.40M, a 10.56% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. paid-in-kind interest for fiscal 2025 was $20.25M, a 31.12% increase from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. paid-in-kind interest for fiscal 2024 was $15.44M.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 7 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $6.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $13.94M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $7.08M 10-Q · filed 2026-05-06 | ||||
| 2025-12-31 | $15.21M 10-KT · filed 2026-03-16 | ||||
| 2025-09-30 | $6.11M 10-Q · filed 2025-11-06 | ||||
| 2025-05-25 | $5.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $10.61M 10-Q · filed 2026-08-05 | $20.25M 10-KT · filed 2026-03-16 | ||
| 2025-02-23 | $5.21M 10-Q · filed 2026-05-06 | ||||
| 2024-08-25 | $4.72M 10-Q · filed 2025-11-06 | $10.75M derived: sum of 2 quarters · filed 2026-03-16 | $14.01M derived: sum of 3 quarters · filed 2026-03-16 | $17.14M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-05-26 | $6.03M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $9.29M derived: sum of 2 quarters · filed 2026-03-16 | $12.42M derived: sum of 3 quarters · filed 2026-03-16 | $15.44M 10-KT · filed 2026-03-16 | |
| 2024-02-25 | $3.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-09 | $6.38M derived: sum of 2 quarters · filed 2024-08-09 | $9.41M 10-Q · filed 2024-08-09 | ||
| 2023-11-26 | $3.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $6.15M 10-Q · filed 2024-08-09 | |||
| 2023-08-27 | $3.02M 10-Q · filed 2024-08-09 | ||||
| 2023-02-26 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-09 | $0.00 derived: sum of 2 quarters · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | ||
| 2022-11-27 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | |||
| 2022-08-28 | $0.00 10-Q · filed 2024-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |